Age: 40.0
Sex: U
Vaccine: COVID19
Symptoms: Anaphylactic reaction, Skin test, Tryptase
Clinical narrative: This literature-study case was reported in a literature article and describes the occurrence of ANAPHYLACTIC REACTION (Anaphylaxis) in a 40-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.      Concurrent medical conditions included Asthma, Latex allergy and Drug allergy.    On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced ANAPHYLACTIC REACTION (Anaphylaxis) (seriousness criterion medically significant). At the time of the report, ANAPHYLACTIC REACTION (Anaphylaxis) outcome was unknown. Possible    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Skin test: negative (Negative) Negative. On an unknown date, Tryptase: 3.8 ug/l 3.8 ug/L - post-2nd dose.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered ANAPHYLACTIC REACTION (Anaphylaxis) to be possibly related.    Patient presented with Generalized hives, shortness of breath, chest tightness, tachycardia as symptoms of anaphylaxis.  Patient experienced Protracted symptoms (5 days).   She received received 2nd dose in high risk clinic; 20 min later developed cough (no other symptoms)  Company comment: This case concerns a 40-year-old patient of unknown with a relevant medical history of Asthma and Drug allergy, who experienced the expected serious event of Anaphylactic reaction after mRNA- 1273 Moderna vaccine (Moderna COVID-19 Vaccine). The event occurred approximately 5 days after the second dose of mRNA- 1273 vaccine, temporal relationship unknown. Clinical manifestations included cough 20 minutes after vaccination and generalized hives, dyspnoea, chest tightness and tachycardia 5 days later. The rechallenge is not applicable, since the event was reported exclusively after the second dose. Previous asthma and Drug allergy remain a confounder. The benefit-risk relationship of mRNA- 1273 vaccine / Moderna COVID-19 Vaccine is not affected by this report   This case was linked to MOD-2021-372464, MOD-2021-372371, MOD-2021-372466 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 03-Nov-2021: Follow up received by safety on 04-Nov-2021. contains no new information. Updated address, phone number and laboratory test from initial report.; Sender's Comments: This case concerns a 40-year-old patient of unknown with a relevant medical history of Asthma and Drug allergy, who experienced the expected serious event of Anaphylactic reaction after mRNA- 1273 Moderna vaccine (Moderna COVID-19 Vaccine). The event occurred approximately 5 days after the second dose of mRNA- 1273 vaccine, temporal relationship unknown. Clinical manifestations included cough 20 minutes after vaccination and generalized hives, dyspnoea, chest tightness and tachycardia 5 days later. The rechallenge is not applicable, since the event was reported exclusively after the second dose. Previous asthma and Drug allergy remain a confounder. The benefit-risk relationship of mRNA- 1273 vaccine / Moderna COVID-19 Vaccine is not affected by this report